^
    Back
    Association details:
    Biomarker:EGFR mutation + EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor) +
    Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lung Cancer
    Title:

    Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

    Published date:
    09/21/2021
    Excerpt:
    Overall, median TTF was 27.7 months (95% CI: 24.0–30.2) and median OS was 36.5 months (95% CI: 32.9–41.8). ORR with afatinib and osimertinib was 74% and 45%. TTF, OS and ORR were generally consistent across subgroups….Sequential afatinib and osimertinib demonstrated encouraging activity in patients with EGFR mutation-positive NSCLC and acquired T790M.
    DOI:
    https://doi.org/10.1016/j.lungcan.2021.09.009